Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS203 combination therapy in B-cell non-Hodgkin lymphoma
CTR20252817Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS203 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
JS203
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20252817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252817.